MIGS stands for minimally invasive glaucoma surgery, a group of procedures designed to lower eye pressure with far less risk and recovery time than traditional glaucoma operations. These surgeries work by improving the eye’s natural drainage of fluid or, in some cases, reducing the amount of fluid the eye produces. They’ve become one of the fastest-growing options in glaucoma treatment, especially for people with mild to moderate disease who want to reduce their dependence on daily eye drops.
How MIGS Works Inside the Eye
Your eye constantly produces a clear fluid called aqueous humor, which nourishes internal structures and then drains out through a mesh-like tissue near the base of the iris. In glaucoma, that drainage system doesn’t work efficiently, so fluid backs up and pressure builds. Over time, elevated pressure damages the optic nerve and causes irreversible vision loss.
The greatest resistance to fluid outflow sits in a thin layer of tissue just in front of a tiny circular channel called Schlemm’s canal. MIGS procedures target this bottleneck in several ways:
- Bypassing the meshwork: A micro-stent is placed through the clogged tissue so fluid flows directly into Schlemm’s canal.
- Removing the meshwork: A strip of the resistant tissue is cut or peeled away to open the drainage path.
- Routing fluid to a different space: Some devices redirect fluid into either the area beneath the clear membrane covering the white of the eye or into a deeper space behind the iris.
- Reducing fluid production: A small amount of energy is applied to the tissue that makes aqueous humor, slowing output.
All of these approaches share the same goal: bringing eye pressure down enough to slow or stop optic nerve damage.
What Makes MIGS Different From Traditional Surgery
Traditional glaucoma surgeries, such as trabeculectomy and tube shunt implants, are powerful pressure-lowering operations, but they come with significant risks. Trabeculectomy creates a new drainage opening through the wall of the eye, which can lead to dangerously low eye pressure (called hypotony), infection of the drainage bleb, and other serious complications. The Tube Versus Trabeculectomy Study reported early complication rates of 22% for tube shunts and 39% for trabeculectomy.
MIGS procedures are defined by five characteristics that set them apart: a high safety profile, minimal disruption of the eye’s normal anatomy, an approach from inside the eye through a tiny corneal incision, meaningful pressure reduction, and fast recovery for the patient. Notably, a systematic review of MIGS outcomes found no reported cases of hypotony, double vision, or infection, complications that are well-known concerns with traditional surgery. The overall complication rate for MIGS was about 16% after excluding transient, harmless blood in the front of the eye, which resolves on its own.
Who Is a Good Candidate
MIGS is typically best suited for people with mild to moderate open-angle glaucoma, particularly those who are already having cataract surgery or who struggle with the cost, side effects, or daily burden of eye drops. Surgeons often match the specific procedure to the severity of the disease. For mild glaucoma, a micro-stent that bypasses the drainage meshwork may be enough. For mild to moderate cases, a procedure that strips away resistant tissue (called goniotomy) is often preferred. Once the disease is moderate to advanced with measurable vision loss, surgeons may open the drainage angle across the full 360 degrees of the eye for a more aggressive pressure drop.
People with very advanced glaucoma who need dramatic pressure lowering may still require traditional surgery. MIGS fills a gap between eye drops and those larger operations, offering a middle step that can delay or even prevent the need for more invasive intervention.
MIGS Combined With Cataract Surgery
One of the most common ways MIGS is performed is at the same time as cataract removal. Both procedures use the same small incision in the cornea, so adding a MIGS step adds only a few minutes to the operation. This combination has grown rapidly over the past decade because of the short surgical times, low complication rates, and faster healing compared to standalone glaucoma surgery.
Two-year data from pivotal clinical trials showed that combining a MIGS device with cataract surgery lowered both eye pressure and the number of daily drops more effectively than cataract surgery alone. Quality-of-life measures improved more in the combined group as well, including visual function scores and ocular surface comfort. That second point matters because glaucoma drops themselves can irritate the eye’s surface and worsen dry eye symptoms. Reducing or eliminating drops after MIGS often provides noticeable day-to-day relief.
Longer-term results are encouraging too. Over five years, patients who received a Schlemm’s canal micro-stent during cataract surgery had a significantly slower rate of visual field loss compared to those who had cataract surgery alone. The number of patients experiencing rapid vision decline was also significantly reduced. For someone with early glaucoma, an early MIGS procedure can both preserve vision longer and delay the need for more invasive surgery down the road.
What Recovery Looks Like
Recovery from MIGS is fast compared to traditional glaucoma operations. Most people notice their vision returning within days to weeks. Blurry vision in the operated eye is normal in the first few days, but it steadily clears. Reading, watching TV, and using phones or computers are generally possible within the first few days after surgery.
Your eye drop routine will change after the procedure. Your surgeon will typically stop one or more of your glaucoma medications and may prescribe short-term anti-inflammatory drops to help the eye heal. The schedule for resuming or discontinuing glaucoma drops varies from person to person, so expect a tailored plan at your follow-up visits. One of the main goals of MIGS is to lighten that daily medication burden, and many patients end up on fewer drops than before, sometimes none at all.
Risks and Limitations
MIGS carries a much lower risk of serious complications than traditional glaucoma surgery, but no procedure is risk-free. The most common issue is a small amount of blood in the front of the eye (hyphema), which typically clears on its own within days. Temporary pressure spikes can also occur in the early postoperative period, though they usually resolve with monitoring or short-term treatment.
The main limitation of MIGS is that it generally produces a more modest pressure reduction than traditional surgery. For someone who needs their eye pressure cut in half, trabeculectomy or a tube shunt may still be the better choice. MIGS works best when the goal is a moderate pressure drop, a reduction in eye drops, or both. If MIGS doesn’t lower pressure enough on its own, it doesn’t burn any bridges. Traditional surgery can still be performed afterward because MIGS leaves the eye’s anatomy largely intact.